Investors following the U.S. cannabis sector often see two distinct operator profiles: large, vertically integrated multi-state companies and smaller, regionally focused cultivators. This comparison looks at GLAS (Glass House Brands Inc.) and TRLV (Trulieve Cannabis Corp.) to show how scale, financial strength, and market reach can differ sharply even inside the same industry. Growth-oriented investors assessing relative performance and risk levels may find the contrast useful, since these two names sit at opposite ends of the sector’s size range. Understanding their business models and recent price behavior helps clarify where each stock fits in the broader cannabis landscape.
GLAS, or Glass House Brands Inc., is a vertically integrated cannabis company centered mainly on the California market. Headquartered in Long Beach, California, and founded in 2015, the company handles greenhouse cultivation, manufacturing, brand development, and retail under names such as Glass House Farms, PLUS Products, Allswell, Forbidden Flowers, and Mama Sue Wellness. It trades on the NYSE and also appears on the OTCQX under the symbol GLASF. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
From a market-positioning standpoint, GLAS is a small-capitalization name, with a market capitalization that has moved in the roughly $120 million to $200 million range in recent weeks. Trailing twelve-month revenue sits near $195 million, while net income stays negative amid ongoing investment and competitive pressure in California’s wholesale cannabis market. In recent trading, the stock has shown considerable volatility and a clear pullback from its 52-week high, highlighting the elevated risk tied to a concentrated, single-state operator.
TRLV, or Trulieve Cannabis Corp., is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. The company cultivates, processes, manufactures, and sells medical and adult-use cannabis, with a strong presence in Florida and additional operations in Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It runs roughly 207 retail dispensaries along with about 3.5 million square feet of cultivation and processing capacity.
With a market capitalization around $1.8 billion and trailing twelve-month revenue of about $1.08 billion, TRLV is considerably larger than many peers and recently became one of the first U.S.-based cannabis companies to uplist to the New York Stock Exchange. The company has produced positive operating profit and levered free cash flow, and it has announced a share repurchase program of up to $50 million. Although the stock has retreated from its 52-week high in recent weeks, its longer-term trend remains positive, with a roughly 80% gain over the trailing 52-week period.
The clearest difference between these two cannabis operators lies in scale and diversification. TRLV operates across multiple states with a leading position in Florida, giving it a wider revenue base and greater geographic resilience than GLAS, whose results are closely tied to California’s wholesale and retail cannabis conditions. On financial fundamentals, TRLV generates positive operating profit and free cash flow, while GLAS continues to report negative net income.
Risk profiles also differ in meaningful ways. TRLV carries a higher beta, reflecting greater sensitivity to broader market moves, yet its fundamentals provide more stability. GLAS, as a small-cap single-state operator, faces concentrated regulatory and pricing risk. In recent momentum, both names have declined from higher levels, but TRLV keeps a stronger trailing 52-week trend, while GLAS has seen a steeper drawdown.
Based on observable factors such as scale, cash-flow generation, geographic diversification, and trend consistency, Tickeron’s AI currently favors TRLV over GLAS. The multi-state operator’s positive operating cash flow, larger revenue base, and recent exchange uplisting represent comparatively stronger catalysts and stability signals. GLAS’s concentrated California exposure and negative earnings introduce greater uncertainty into its outlook. These observations reflect probabilistic positioning rather than a definitive prediction, and conditions can shift as new data emerges.
I’ve found Tickeron’s Trending AI Robots page helpful when reviewing how automated strategies are currently positioned across sectors like cannabis. It offers a focused view of bots that adapt to shifting conditions, letting me compare different approaches without relying on any single method.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TRLV saw its Momentum Indicator move below the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 78 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 30 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
TRLV moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Indicator entered the oversold zone -- be on the watch for TRLV's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 186 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
TRLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 135 of 157 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.901) is normal, around the industry mean (6.379). P/E Ratio (-4.680) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric